Sutro Biopharma (STRO) Revenue (2017 - 2025)

Sutro Biopharma has disclosed Revenue across 9 years of filings, most recently posting $6.6 million for Q4 2025.

• Revenue for Q4 2025 came in at $6.6 million, down 55.43% year-over-year; the trailing twelve-month figure through Dec 2025 was $85.7 million (up 58.37% YoY), and the FY2025 annual result was $102.5 million, up 65.18% from the prior year.
• Revenue came in at $6.6 million for Q4 2025 at Sutro Biopharma, down from $9.7 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $113.7 million in Q4 2023 to a low of $5.7 million in Q1 2025.
• The 5-year median for Revenue is $12.8 million (2023), against an average of $21.2 million.
• Across the five-year window, Revenue soared 1217.44% in 2023 and slumped 86.98% in 2024, its largest moves.
• Sutro Biopharma's Revenue stood at $10.7 million in 2021, then declined by 18.98% to $8.6 million in 2022, then jumped by 1217.44% to $113.7 million in 2023, then plunged by 86.98% to $14.8 million in 2024, then sank by 55.43% to $6.6 million in 2025.
• The last three Revenue figures came in at $6.6 million (Q4 2025), $9.7 million (Q3 2025), and $63.7 million (Q2 2025), per Business Quant data.